Healius Limited (AU:HLS) has released an update.
Healius Limited has announced significant changes, including the sale of Lumus Imaging to Affinity Equity Partners, as part of a strategic review aimed at focusing on its core pathology operations. New leadership under CEO Paul Anderson is driving efforts to improve performance amid external challenges like inflation and stagnant pathology indexation. The proceeds from the Lumus sale will help reduce debt and refocus Healius’ business strategy.
For further insights into AU:HLS stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
